コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 fic activities) of less than 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mouse, respective
7 radioembolization dosages from 46.3 to 105.1 MBq were infused, resulting in average absorbed doses of
9 (111)In-cetuximab-F(ab')2 (5 mug, 28 +/- 6.1 MBq, 24 h after injection), followed by PET imaging with
11 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol) peptide amount of (177)Lu-NeoBOMB1, after w
12 l (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol)
16 ution (7 d after tracer administration, 1.11 MBq/animal, n = 4-6/group) was performed in wild-type an
18 either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were inje
19 ed with 17.5 d (IQR, 5.5-22.5 d) for the 110-MBq and 41.0 d (IQR, 27.5-55.0) for the 165-MBg group.
23 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were injected with ve
24 te-buffered saline, 6 MBq (213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (177)Lu-IMP288 was 22, 31
25 of the kidneys of mice treated with 17 or 12 MBq (213)Bi-IMP288 showed signs of tubular damage, indic
29 The median administered activity was 122 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (
30 e were injected with either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1
31 diac myocardial blood flow imaging were 3-14 MBq/kg, 1.5-4.0, 22-64 Mcps singles and 4-14 Mcps prompt
33 (361 +/- 60 MBq) and high-dose (725 +/- 142 MBq) (99m)Tc-tetrofosmin scans were included, with 6-min
35 riod at specific activities of less than 148 MBq/mg; however, specific activities up to 592 MBq/mg co
37 q/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, o
39 ble molar doses of TF2 and approximately 150 MBq of (68)Ga-IMP288 after different pretargeting time i
40 The highest organ-absorbed doses (for 150 MBq injected) were found in the urinary bladder wall (12
41 ncreased (99m)Tc-nanocolloid activity of 150 MBq to facilitate nodal detection against the gamma-prob
45 DOTATOC (15 mug of peptide) and 2 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of p
47 0 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI attenuation corrected (AC) by CT and
48 0 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI attenuation corrected (AC) by CT and
49 ents were injected intravenously with 90-158 MBq of (68)Ga-pentixafor (mean +/- SD, 134 +/- 25 MBq),
51 harmaceutical in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10
53 l administered (177)Lu-DOTA-Bn activity, 167 MBq/mouse; estimated radiation absorbed dose to tumor, 1
54 , the effect of (213)Bi-IMP288 (6, 12, or 17 MBq) and (177)Lu-IMP288 (60 MBq) on tumor growth and sur
57 The median administered activity was 170 MBq in 12 (111)In-pentetreotide SPECT/CT studies and 186
61 CZT camera, (99m)Tc-tetrofosmin (358 +/- 177 MBq) was administered and dual-isotope acquisition was p
62 (89)Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific mem
66 In human PET studies, [(18) F]Nifene (185 MBq; <0.10 mug) was well tolerated with no adverse effec
71 otracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific membrane antigen (n = 7
73 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (18)F-FDOPA PET/CT studies, and 176 MBq in 13
76 s were identified correctly with a dose of 2 MBq/kgBW; Likert scores did not differ significantly.
81 er with 5 g 3-O-methylglucose (3-OMG) and 20 MBq (99m)Tc-sulfur colloid (total volume 200 mL), was gi
82 scalating injected activities (10, 15 and 20 MBq/kg) of (177)Lu-lilotomab satetraxetan and with diffe
85 han 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mouse, respectively, uptake of (68)Ga-aqui
86 c point of view, an administered dose of 200 MBq for (64)CuCl2 translated into a 5.7-mSv effective do
87 hest after intravenous administration of 200 MBq of (18)F-fluoromethylcholine, followed by a whole-bo
90 photodiode was illuminated by a standard 206 MBq (55)Fe radioisotope X-ray source and characterised o
94 or these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a (68)Ga-PSMA-617 PET/CT
95 in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas co
97 f (68)Ga-pentixafor (mean +/- SD, 134 +/- 25 MBq), and a series of 3 rapid multiple-bed-position whol
98 diameter, mice were injected with 0.75-2.25 MBq ( approximately 10 mug) of an engineered radiotracer
99 0 h after administration of approximately 25 MBq of (124)I and subsequently underwent imaging 5-10 d
101 ry, received similar activities of about 250 MBq of (18)F-DCFPyL and (18)F-PSMA-1007 48 h apart and w
102 n PET acquisition 2 h after injection of 250 MBq of (18)F-AV-133, and the resulting images were quant
107 enous injection of the tracer (198.3 +/- 3.3 MBq), 3 successive whole-body (vertex to mid thigh) PET/
108 mean +/- SEM) 4 h after injection of 7.3-9.3 MBq of (18)F-FVIIai and with an average maximum uptake i
111 In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA,Tyr(3)]octreotate, tumor uptake cou
113 n studies with (177)Lu-DOTA-JR11 (0.5 mug/30 MBq) resulted in the highest tumor radiation dose of 1.8
115 0 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total
117 with (64)Cu-labeled trastuzumab (0.016-0.368 MBq/mug, 67 nM) for 18 h versus the absorbed dose follow
118 A specific activity of 55.5 MBq/nmol (0.37 MBq/mug) was reproducibly obtained with [(89)Zr]Zr-darat
120 c) mertiatide (MAG3) in the range of 300-370 MBq (approximately 8-10 mCi) contribute to image interpr
121 oses of (99m)Tc-MAG3 in the range of 300-370 MBq (approximately 8-10 mCi) do not affect the relative
123 45 (291 +/- 67 MBq) and 1-min (15)O-H2O (370 MBq) scans were obtained in 35 age-matched elderly subje
125 ognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min begi
126 Dosimetry calculations predict that 370 MBq of (51)Mn in an adult human male would yield an effe
129 uired as 4 x 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and tran
131 quisition for RVH and a high activity (303.4 MBq +/- 48.1) acquisition after administration of enalap
132 mouse at 5-min frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clea
133 tion of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time-of-flight-enabled simult
135 acers, for which an injected activity of 400 MBq corresponds to a total effective dose of approximate
137 ganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of (18)F-MFBG intravenously followed by se
138 t maximal dosages; 2 patients received a 444 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of ars
139 , patients received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with im
149 icking imaging was achieved by injecting 5.5 MBq of 99mTc-anti-CD56 mAb in SCID mice bearing ARO tumo
150 In a separate session, patients received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi])
152 semiefficient doses of (177)Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide phosphoribosylt
157 osmin stress (5 min; mean +/- SD, 350 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI
158 osmin stress (5 min; mean +/- SD, 350 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI
159 nders received two doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan administered 1 we
160 S5161 for a standard single injection of 555 MBq (15 mCi) will result in an effective dose equivalent
165 q/mg; however, specific activities up to 592 MBq/mg could be achieved with an incubation period.
166 small-animal SPECT/CT imaging (18.5 +/- 2.6 MBq) with 25 mug of (111)In-labeled ADCs were performed
167 assessed using (99m)Tc-tetrofosmin (26 +/- 6 MBq), (123)I-MIBG (54 +/- 14 MBq), and a CZT camera.
169 ps treated with phosphate-buffered saline, 6 MBq (213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (1
171 213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (177)Lu-IMP288 was 22, 31, 45, and 42 d, respectivel
173 7 at different formulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or
176 ormulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol
178 enic trioxide; and 3 patients received a 666 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of ars
179 lanned treatment was (131)I-MIBG (444 or 666 MBq/kg) intravenously on day 1 plus arsenic trioxide (0.
181 +/- 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time
183 count rate from a mouse-sized phantom at 3.7 MBq was 11.1 kcps and peaked at 20.8 kcps at 14.5 MBq.
185 re than 97% and a specific activity of 3,700 MBq/mg and retaining biochemical integrity and binding a
188 ents received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methion
189 er a minimum 4-h fast, patients received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum
192 with colorectal cancer received 36.9 +/- 0.8 MBq of (89)Zr-cetuximab within 2 h after administration
193 protocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA
194 protocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA
198 one using buffered eluate fractions (600-800 MBq, pH 2) of an SnO2-based generator, affording the rad
200 received (89)Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy.
201 received (89)Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy.
206 on was determined after a low activity (62.9 MBq +/- 40.7) baseline acquisition for RVH and a high ac
208 d dose of (131)I-MIBG to blood was 0.134 cGy/MBq, well below myeloablative levels in all patients.
210 ghest tumor radiation dose of 1.8 +/- 0.7 Gy/MBq, 4.4 times higher than the highest tumor radiation d
211 he 10 3D PET systems if the maximum injected MBq/kg values are respected to limit peak dead-time loss
217 , at 0.047 +/- 0.008 and 0.067 +/- 0.007 mGy/MBq for the 2- and 4-h voiding intervals, respectively.
218 mean total-body dose was 0.011 +/- 0.011 mGy/MBq, and the effective dose was 0.023 +/- 0.012 mSv/MBq.
221 marrow was 0.13, 0.086, 0.33, and 0.068 mGy/MBq after rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq
226 /MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with an average effective dose of 0.54 +/- 0.07 mS
230 r wall as the dose-limiting organ (0.200 mGy/MBq), whereas the dose to the red marrow was 0.006 mGy/M
231 an +/- SD) were the liver (1.75 +/- 0.21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart
233 .21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with a
236 dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an
240 d to the red marrow were 177-994 and 1-5 mGy/MBq from activity on the bone surfaces and from activity
245 The mean absorbed doses to RM were 0.9 mGy/MBq for arm 1 (lilotomab+) and 1.5 mGy/MBq for arm 2 (li
249 labeled tracers, such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly becau
252 were 0.013 +/- 0.004 and 0.014 +/- 0.004 mSv/MBq, respectively, depending on the voiding schedule.
254 ith an effective dose estimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-MBq
261 the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marrow,
263 d effective dose was 2.4E-02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity
265 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary glands (parotids, 0.031 +/- 0.011 mSv
271 doses were the thyroid (0.135 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary gl
273 ided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the hum
276 doses in source organs ranged from 7.7 muGy.MBq(-1) in the brain to 12.7 muGy.MBq(-1) in the spleen.
278 effective dose (+/-SD) was 4.5 +/- 0.5 muSv.MBq(-1)The effective dose of (11)C-GMOM is at the lower
279 Effective doses were 3.41 +/- 0.06 muSv/MBq for (11)C-elacidar and 3.62 +/- 0.11 muSv/MBq for (1
284 +/- 4.9, 31.0 +/- 2.4, and 20.9 +/- 5.2 muSv/MBq for the no-voiding, 2.5-h-voiding, and 1-h-voiding m
287 he liver (43.1 +/- 4.9 and 68.9 +/- 9.4 muSv/MBq in reference human male and female phantoms, respect
288 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/- 1.67 muSv/MBq), and spleen (9.49 +
289 acceptable, with effective doses of 9.5 muSv/MBq (intravenous administration) and 18.1 muSv/MBq (oral
293 he total absorbed body dose was low (<7 muSv/MBq); the effective dose was estimated at 17 muSv/MBq.
294 he urinary bladder wall (14.68 +/- 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/-
296 of 54% per Gy of X-ray radiation and 15% per MBq/ml of 2-deoxy-2-[(18)F]-fluoro-d-glucose ([(18)F]FDG
297 erall absorbed dose to the normal organs per MBq of (131)I administered, between the 2 TSH stimulatio
298 n patients received 325 +/- 29 (mean +/- SD) MBq of the cyclotron-produced (99m)Tc-NaTcO4, whereas th
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。